BNP Paribas Bonus Zert 6MK 30.12..../ DE000PC67M47 /
08/11/2024 21:40:14 | Chg.+2.310 | Bid21:59:27 | Demandez à- | Sous-jacent | Prix d'exercice | Date d'expiration | Type d'option |
---|---|---|---|---|---|---|---|
95.370EUR | +2.48% | 95.370 Bid taille: 1,500 |
- Ask la taille: - |
MERCK CO. D... | - - | 30/12/2024 | Call |
GlobeNewswire
31/07
Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease
GlobeNewswire
17/07
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease a...
GlobeNewswire
09/07
Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination ...
GlobeNewswire
25/06
Qure.ai announces strategic investment by Merck Global Health Innovation Fund to boost innovation of...
GlobeNewswire
18/06
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for ...
GlobeNewswire
06/06
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepin...
GlobeNewswire
03/06
Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, ...
GlobeNewswire
29/05
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio fo...
GlobeNewswire
07/05
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
06/05
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Person...
GlobeNewswire
06/03
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Can...
- La première page
- Retour
- 1
- 2
- 3
- 4
- Suivant
- La dernière page